Back

The Pediatric MATCH Screening Trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Leffin, Melissa; Spinelli, Jennifer; Parker, Melanie; Short, Caitlyn

  • IRB No: APEC1621SC

    Protocol Abbrev: APEC1621SC

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase II

    Age Group: Adult;Pediatric

    Secondary Protocol No: APEC1621SC

    Treatment: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Mutation Carrier Screening

    ClinicalTrials.gov ID: NCT03155620

  • Objective

    I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.

    II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs.

    III. To determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents.

  • Key Eligibility

    Sexes Eligible for Study - All
    Ages - 12 Months to 21 Years (Child, Adult)
    Accepts Healthy Volunteers - No